Related Experiment Videos
Effect of rat phosphorylcholine-binding protein on platelet aggregation
A Nagpurkar1, E Randell, S Choudhury
1Department of Biochemistry, Memorial University of Newfoundland, St. John's, Canada.
Biochimica Et Biophysica Acta
|October 13, 1988
Summary
Phosphorylcholine-binding protein (PCBP) in rat serum inhibits platelet aggregation. This protein may explain why rat platelets don't aggregate with platelet-activating factor (PAF).
Area of Science:
- Biochemistry
- Hematology
- Immunology
Background:
- Phosphorylcholine-binding protein (PCBP), also known as rat C-reactive protein, is naturally present in rat serum.
- Platelet aggregation is a critical process in hemostasis and thrombosis.
Purpose of the Study:
- To investigate the role of rat serum PCBP in platelet aggregation.
- To determine if PCBP affects ADP- and platelet-activating factor (PAF)-induced platelet aggregation in rats and humans.
Main Methods:
- Used washed rat platelets and platelet-rich plasma from rats and humans.
- Administered PCBP and observed its effect on platelet aggregation induced by ADP and PAF.
- Utilized rabbit antiserum against PCBP and phosphorylcholine to further elucidate PCBP's function.
Main Results:
- PCBP demonstrated dose-dependent inhibition of ADP- and PAF-induced platelet aggregation in both rat and human platelets.
- Rat platelets, typically unresponsive to PAF, aggregated when treated with anti-PCBP antiserum, suggesting PCBP's inhibitory role.
- The inhibitory effect of PCBP on ADP-induced aggregation was reversible by adding phosphorylcholine.
Conclusions:
- Rat serum PCBP likely causes the refractory response of rat platelets to PAF.
- PCBP may inhibit platelet aggregation by binding to platelet surface phospholipids.